Evidence map›Paper›PMID 42780946›Full record

Trial reportFrontiers in nutrition2026

Efficacy and safety of a sustained release ashwagandha root extract capsules on muscle strength and cardiorespiratory endurance in recreationally active individuals: a randomized, double-blind, placebo-controlled trial.

Shefali Thanawala, Rajat Shah, Alphy Lopes, Girish Rudrappa, Prabakaran Desomayanandam, Sahitya Srinivas

Abstract readClinical Trial
In one paragraph

Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shefali ThanawalaMedical Science and Research, Nutriventia Private Limited, Mumbai, Maharashtra, India.
Rajat ShahExecutive Management, Nutriventia Private Limited, Mumbai, Maharashtra, India.
Alphy LopesMedical Science and Research, Nutriventia Private Limited, Mumbai, Maharashtra, India.
Girish RudrappaOrthopedics Department, Rajalakshmi Hospital and Research Center, Bangalore, Karnataka, India.
Prabakaran DesomayanandamClinical Operations, Invitro Research Solutions Private Limited, Bangalore, Karnataka, India.
Sahitya SrinivasClinical Operations, Invitro Research Solutions Private Limited, Bangalore, Karnataka, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Previous studies suggest that conventional Ashwagandha ( Methods: Eligible participants aged 25-50 years received AshwaSR 300 mg or placebo capsules once daily for 90 days. Changes in one-repetition maximum (1-RM) bench press, maximal oxygen uptake (VO Results: Of 84 enrolled participants, 83 completed the study (AshwaSR, Conclusion: Three-months supplementation with AshwaSR 300 mg/day was safe and effective in improving muscular strength, cardiorespiratory endurance, and overall wellbeing in recreationally active healthy adults. Clinical trial registration: CTRI/2025/04/084383, https://ctri.nic.in.

Indexed as

cardiorespiratory endurancemuscle damagemuscle strengthphysical performancequality of liferecoveryWithania somnifera

Identifiers

PMID42780946
PMCPMC13597949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.